Citigroup Inc. grew its position in Kymera Therapeutics, Inc. (NASDAQ:KYMR – Free Report) by 55.0% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 204,731 shares of the company’s stock after buying an additional 72,647 shares during the period. Citigroup Inc. owned approximately 0.37% of Kymera Therapeutics worth $6,066,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Avoro Capital Advisors LLC increased its holdings in Kymera Therapeutics by 77.5% in the 4th quarter. Avoro Capital Advisors LLC now owns 3,850,000 shares of the company’s stock worth $96,096,000 after buying an additional 1,680,770 shares in the last quarter. State Street Corp grew its stake in shares of Kymera Therapeutics by 67.8% in the second quarter. State Street Corp now owns 3,514,438 shares of the company’s stock worth $69,199,000 after acquiring an additional 1,419,877 shares during the period. Price T Rowe Associates Inc. MD grew its stake in shares of Kymera Therapeutics by 34.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,224,686 shares of the company’s stock worth $102,874,000 after acquiring an additional 1,329,481 shares during the period. Wellington Management Group LLP raised its holdings in shares of Kymera Therapeutics by 19.7% during the first quarter. Wellington Management Group LLP now owns 3,225,749 shares of the company’s stock valued at $136,514,000 after purchasing an additional 530,935 shares during the last quarter. Finally, Artal Group S.A. boosted its holdings in Kymera Therapeutics by 33.3% in the fourth quarter. Artal Group S.A. now owns 2,000,000 shares of the company’s stock worth $49,920,000 after purchasing an additional 500,000 shares during the last quarter.
Kymera Therapeutics Price Performance
Shares of KYMR stock opened at $19.86 on Friday. Kymera Therapeutics, Inc. has a one year low of $18.53 and a one year high of $39.85. The company’s fifty day moving average price is $21.34 and its 200-day moving average price is $26.93. The company has a market capitalization of $1.10 billion, a price-to-earnings ratio of -7.20 and a beta of 1.48.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on KYMR. HC Wainwright reiterated a “buy” rating and set a $85.00 target price on shares of Kymera Therapeutics in a research note on Friday, August 4th. Stifel Nicolaus raised their target price on Kymera Therapeutics from $48.00 to $52.00 and gave the stock a “buy” rating in a research report on Monday, August 7th. Morgan Stanley reduced their price target on shares of Kymera Therapeutics from $39.00 to $37.00 and set an “equal weight” rating for the company in a research report on Tuesday. Truist Financial assumed coverage on shares of Kymera Therapeutics in a report on Friday, June 30th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Credit Suisse Group upped their target price on shares of Kymera Therapeutics from $36.00 to $37.00 and gave the company a “neutral” rating in a report on Friday, August 4th. Three analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $48.10.
Kymera Therapeutics Profile
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.
- Five stocks we like better than Kymera Therapeutics
- How to Invest in Lithium and Lithium Stocks
- 2 Stocks That Doubled EPS Estimates and Flashing Buy Signals
- How to Invest in Hotel Stocks
- Toyota vs Tesla: The Tortoise And The Hare Race Has A New Meaning
- Do ETFs Pay Dividends? What You Need to Know
- 5 Critical Takeaways From MongoDB’s Q2 Results for AI Investors
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.